Previous close | 84.51 |
Open | 83.52 |
Bid | 0.00 x 900 |
Ask | 0.00 x 900 |
Day's range | 81.39 - 84.14 |
52-week range | 67.13 - 131.10 |
Volume | |
Avg. volume | 4,568,261 |
Market cap | 50.772B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | 31.71 |
EPS (TTM) | 2.59 |
Earnings date | 24 Apr 2023 - 28 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 87.95 |
Edwards Lifesciences ( NYSE:EW ) Full Year 2022 Results Key Financial Results Revenue: US$5.38b (up 2.9% from FY 2021...
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.